Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $365,317.56 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 33,732 shares of the firm’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $10.83, for a total transaction of $365,317.56. Following the completion of the sale, the executive vice president now directly owns 668,977 shares of the company’s stock, valued at approximately $7,245,020.91. This represents a 4.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

David Sponsel also recently made the following trade(s):

• On Monday, February 24th, David Sponsel sold 12,946 shares of Alphatec stock. The shares were sold at an average price of $10.73, for a total value of $138,910.58.
• On Monday, February 3rd, David Sponsel sold 36,256 shares of Alphatec stock. The shares were sold at an average price of $11.42, for a total transaction of $414,043.52.
• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The stock was sold at an average price of $10.00, for a total transaction of $2,380.00.

Alphatec Price Performance

Shares of Alphatec stock traded down $0.79 during mid-day trading on Monday, reaching $9.67. 3,116,344 shares of the stock traded hands, compared to its average volume of 1,980,921. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The business has a 50-day moving average of $10.91 and a 200 day moving average of $8.64. The stock has a market capitalization of $1.39 billion, a PE ratio of -7.55 and a beta of 1.39. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $14.88.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The firm had revenue of $176.79 million during the quarter, compared to analysts’ expectations of $172.74 million. On average, analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Hedge Funds Weigh In On Alphatec

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Royal Bank of Canada boosted its holdings in shares of Alphatec by 171.2% during the 4th quarter. Royal Bank of Canada now owns 3,185,283 shares of the medical technology company’s stock worth $29,240,000 after purchasing an additional 2,010,806 shares during the last quarter. American Century Companies Inc. lifted its position in Alphatec by 36.5% during the fourth quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company’s stock worth $45,800,000 after buying an additional 1,334,780 shares in the last quarter. Nuveen Asset Management LLC boosted its stake in Alphatec by 78.4% during the fourth quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company’s stock worth $23,730,000 after buying an additional 1,136,330 shares during the last quarter. Marshall Wace LLP grew its holdings in Alphatec by 139.2% in the 4th quarter. Marshall Wace LLP now owns 1,773,246 shares of the medical technology company’s stock valued at $16,278,000 after buying an additional 1,032,070 shares in the last quarter. Finally, Emerald Advisers LLC increased its stake in shares of Alphatec by 112.4% in the 4th quarter. Emerald Advisers LLC now owns 1,456,033 shares of the medical technology company’s stock worth $13,366,000 after acquiring an additional 770,586 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ATEC shares. Piper Sandler boosted their price objective on shares of Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Barclays upped their price target on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price objective on shares of Alphatec in a research note on Thursday, February 27th. Finally, StockNews.com raised shares of Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.